MASSERINI, MASSIMO ERNESTO
 Distribuzione geografica
Continente #
NA - Nord America 13.734
EU - Europa 7.701
AS - Asia 4.031
SA - Sud America 314
AF - Africa 59
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 24
Totale 25.890
Nazione #
US - Stati Uniti d'America 13.355
DE - Germania 1.359
CN - Cina 1.349
IT - Italia 1.205
SE - Svezia 1.132
SG - Singapore 1.021
RU - Federazione Russa 985
HK - Hong Kong 963
IE - Irlanda 870
UA - Ucraina 688
GB - Regno Unito 450
CA - Canada 347
BR - Brasile 259
FI - Finlandia 237
IN - India 202
FR - Francia 165
PL - Polonia 134
VN - Vietnam 134
AT - Austria 109
DK - Danimarca 84
BE - Belgio 68
KR - Corea 67
IR - Iran 62
NL - Olanda 59
TR - Turchia 47
BG - Bulgaria 37
ZA - Sudafrica 28
ID - Indonesia 27
JP - Giappone 27
ES - Italia 26
MX - Messico 24
PT - Portogallo 24
AU - Australia 23
EU - Europa 23
TW - Taiwan 16
CH - Svizzera 15
CZ - Repubblica Ceca 15
AR - Argentina 13
CL - Cile 13
IQ - Iraq 13
RO - Romania 13
IL - Israele 12
BD - Bangladesh 11
PK - Pakistan 11
VE - Venezuela 11
EG - Egitto 10
MY - Malesia 8
EC - Ecuador 6
HU - Ungheria 6
TH - Thailandia 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
GR - Grecia 5
JO - Giordania 5
LB - Libano 5
MA - Marocco 5
NP - Nepal 4
NZ - Nuova Zelanda 4
BO - Bolivia 3
JM - Giamaica 3
LK - Sri Lanka 3
LT - Lituania 3
MD - Moldavia 3
MO - Macao, regione amministrativa speciale della Cina 3
MU - Mauritius 3
NO - Norvegia 3
PY - Paraguay 3
SA - Arabia Saudita 3
YE - Yemen 3
AO - Angola 2
BB - Barbados 2
CI - Costa d'Avorio 2
CO - Colombia 2
DZ - Algeria 2
ET - Etiopia 2
GE - Georgia 2
KE - Kenya 2
KH - Cambogia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
QA - Qatar 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BH - Bahrain 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HN - Honduras 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MK - Macedonia 1
NG - Nigeria 1
Totale 25.889
Città #
Ann Arbor 2.238
Woodbridge 1.577
Chandler 1.058
Hong Kong 938
Houston 865
Dublin 846
Fairfield 832
Jacksonville 752
Frankfurt am Main 727
Singapore 656
Ashburn 655
Wilmington 610
Dearborn 597
Milan 542
Seattle 387
Santa Clara 327
New York 313
Cambridge 293
Princeton 278
Nanjing 223
Beijing 215
Shanghai 164
Lachine 127
Kraków 114
Lawrence 110
Altamura 103
Toronto 99
Vienna 93
Helsinki 92
Moscow 84
Nanchang 82
Guangzhou 80
Council Bluffs 78
Hangzhou 71
Boardman 68
Ottawa 66
San Diego 66
Brussels 62
Dong Ket 55
Andover 51
Changsha 50
Fremont 49
Los Angeles 48
Tianjin 44
Seoul 43
Shenyang 43
Wayne 43
Falls Church 38
Hebei 36
Jiaxing 36
Jinan 36
Plovdiv 36
Munich 32
Mountain View 31
Nürnberg 31
Rome 31
Hefei 30
Zhengzhou 28
Auburn Hills 27
Kunming 27
Chicago 26
Columbus 26
London 25
Norwalk 24
Jakarta 23
The Dalles 23
Dallas 22
Grafing 21
Ningbo 21
Huizen 20
Redmond 20
Pune 19
São Paulo 19
Montréal 16
New Delhi 15
Brooklyn 14
Düsseldorf 14
Edmonton 14
Nuremberg 14
Taizhou 14
Detroit 13
Lecco 13
San Mateo 12
Stockholm 12
Taipei 12
Ahmedabad 11
Monmouth Junction 11
Washington 11
Amsterdam 10
Boston 10
Fuzhou 10
Hanoi 10
Leawood 10
Mumbai 10
Philadelphia 10
Segrate 10
University Park 10
Zanjan 10
Lauterbourg 9
Palermo 9
Totale 17.936
Nome #
Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide 534
Evolution of Nanoparticle Protein Corona across the Blood-Brain Barrier 375
Novel Antitransferrin Receptor Antibodies Improve the Blood-Brain Barrier Crossing Efficacy of Immunoliposomes 363
Investigation of Functionalized Poly(N,N-dimethylacrylamide)-block-polystyrene Nanoparticles As Novel Drug Delivery System to Overcome the Blood-Brain Barrier in Vitro 357
Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide 354
Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer's disease 327
THE TOXICITY OF AMYLOID-BETA OLIGOMERS AND TAU HYPERPHOSPHORYLATION ARE PREVENTED FROM LIPID-BASED NANOPARTICLES IN HUMAN PRIMARY FIBOBLASTS 313
The ability of liposomes, tailored for blood-brain barrier targeting, to reach the brain is dramatically affected by the disease state 307
Nanomedicine for the treatment of Alzheimer's disease 302
Morphogenic effect of common solvent in the self-assembly behavior of amphiphilic PEO-b-PLA 300
Modulation of the intrinsic neuronal excitability by multifunctional liposomes tailored for treatment of Alzheimer’s disease 283
Evaluation of gold nanoparticles biocompatibility: a multiparametric study on cultured endothelial cells and macrophages 278
Lipid-based nanoparticles counteract the oligomer abeta toxicity and tau phosphorylation in an ex-vivo biomolecular model of alzheimer disease 278
Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model 277
Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease 277
Enhanced brain targeting of engineered solid lipid nanoparticles 275
Versatile and Efficient Targeting Using a Single Nanoparticulate Platform and its Application to Cancer and Alzheimer's Disease 274
Solid Lipid Nanoparticles: a strategy to overcome the blood-brain barrier 260
TrkA pathway activation induced by amyloid-beta (Abeta) 257
18F-labeling syntheses and preclinical evaluation of functionalized nanoliposomes for Alzheimer's disease 255
Characterization of prion protein-enriched domains, isolated from rat cerebellar granule cells in culture 252
Curcumin derivatives as new ligands of Aβ peptides 252
Prion protein structure is affected by pH-dependent interaction with membranes: a study in a model system 248
Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: Implications for therapy of Alzheimer disease 246
Aβ42 production in brain capillary endothelial cells after oxygen and glucose deprivation 234
Protein-functionalized nanoparticles derived from end-functional polymers and polymer prodrugs for crossing the blood-brain barrier 233
Effect of modified collagen on amyloid beta peptide aggregation 231
Peripheral sink effect as possible nanotherapeutic strategy for alzheimer’s disease: an ex vivo study 230
Iron oxide nanoparticles surface coating and cell uptake affect biocompatibility and inflammatory responses of endothelial cells and macrophages 229
Functionalized liposomes and phytosomes loading Annona muricata L. aqueous extract: Potential nanoshuttles for brain-delivery of phenolic compounds 227
Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimer Disease 226
Effect of nanoparticles binding β-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages 223
Developmental changes in the protein composition of sphingolipid- and cholesterol-enriched membrane domains of rat cerebellar granule cells 221
Liposomes functionalized to overcome the blood–brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model 218
Amyposomes: a nanomedicine designed for treatment of Alzheimer disease 218
Abeta peptide toxicity is reduced after treatments decreasing phosphatidylethanolamine content in differentiated neuroblastoma cells 216
Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide 212
Pin1, a new player in the fate of HIF-1α degradation: an hypothetical mechanism inside vascular damage as Alzheimer’s disease risk factor 212
Membrane features and activity of GPI-anchored enzymes: alkaline phosphatase reconstituted in model membranes 211
Inhibition of murine leukemia (WEHI-3B and L1210) proliferation by cholera toxin B subunit 208
Pin1: a new outlook in Alzheimer's disease 205
Enhanced folate binding of cultured fibroblasts from Alzheimer's disease patients 201
Interactions of proteins with ganglioside-enriched microdomains on the membrane: the lateral phase separation of molecular species of GD1a ganglioside, having homogeneous long-chain base composition, is recognized by Vibrio cholerae sialidase 201
Role of lipid rafts and GM1 in the segregation and processing of Prion Protein 201
Immunoseparation of Prion protein-enriched domains from other detergent-resistant membrane fractions, isolated from neuronal cells 200
Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis 196
AUTOPHAGY ALTERATION UNDER ISCHEMIC CONDITION: A POSSIBLE LINK TO ALZHEIMER'S DISEASE 196
A nanomedicine-based therapeutic approach restores memory and ameliorates amyloid pathology in Alzheimer's mouse models 196
Detection and Characterization of Different Brain-Derived Subpopulations of Plasma Exosomes by Surface Plasmon Resonance Imaging 196
Solid Lipid Nanoparticles: a strategy to overcome the blood-brain barrier 195
Enhanced brain targeting of engineered solid lipid nanoparticles 194
Ceramides and sphingomyelinases in senile plaques 193
Pin1 affects Tau phosphorylation in response to Abeta oligomers 192
Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in alzheimer’s disease mouse models 192
Fuc-GM1 ganglioside mimics the receptor function of GM1 for cholera toxin 190
Study of the effects of nanoliposomes engineered for the treatment of Alzheimer's disease on the electrical activity of cortical neurons 190
mApoE-Functionalized Nanoliposomes Delivering Doxorubicin and Ultrasmall Superparamagnetic Iron Oxide to Glioblastoma Cells Characterized by TEM and Confocal Microscopy 190
Beta-amyloid (25-35) enhances lipid metabolism and protein ubiquitination in cultured neurons 189
ALCOHOL AND NEURAL LIPIDS 187
Lipid-based nanoparticles with high binding affinity for amyloid-b1e42 peptide 187
Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer patients 185
Dependence of rat liver CMP-N-acetylneuraminate:GM1 sialyltransferase (SAT IV) activity on the ceramide composition of GM1 ganglioside 185
THE TOXIC EFFECT OF ABETA OLIGOMERS MAY BE REDUCED BY LIPID-BASED NANOPARTICLES IN HUMAN EX-VIVO MODELS 185
Lipid-based nanoparticles as a potential tool to deplete abeta. Toward new therapeutic strategies for Alzheimer’s disease? 184
Two tail-anchored protein variants, differing in transmembrane domain length and intracellular sorting, interact differently with lipids 181
Age-related changes in the ceramide composition of the major gangliosides present in rat brain subcellular fractions enriched in plasma membranes of neuronal and myelin origin 180
Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice 180
Role of phosphatidylethanol in membranes. Effects on membrane fluidity, tolerance to ethanol, and activity of membrane-bound enzymes 179
Nanotechnology for neurodegenerative disorders 179
The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue 177
Nanomedicine for the treatment of Alzheimer's disease 177
Attempt of neuroprotective response of rat cultured hippocampal neurons against Abeta insult 175
Palmitic is the main fatty acid carried by lipids of detergent-resistant membrane fractions from neural and non-neural cells 173
Liposomes functionalized with acidic lipids rescue Aβ-induced toxicity in murine neuroblastoma cells 173
Ischemic conditions and β-secretase activation: The impact of membrane cholesterol enrichment as triggering factor in rat brain endothelial cells 173
A photo-reactive derivative of ganglioside GM1 specifically cross-links VIP21-caveolin on the cell surface 172
Thermotropic behavior of fatty acid ethyl esters in phospholipid liposomes 171
Methyl-β-cyclodextrin treatment affects the thermotropic behaviour of membranes and detergent-resistant membrane fractions of cultured A431 cells 171
A surveillance system for early-stage diagnosis of endogenous diseases by swarms of nanobots 170
Lipid-based nanoparticles (NPs) with high binding affinity for amyloid-beta1-42 peptide modulate the barrier properties of a monolayer of endothelial cells 169
Effect of curcumin-associated and lipid ligand functionalised nanoliposomes on aggregation of the Alzheimer's Aβ peptide 168
New tricyclic compounds, process for their manufacture and their use as ligands of beta-alyloid peptides 167
A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1 Delta E9 Mouse Model of Alzheimer's Disease 167
Influence of glycolipid oligosaccharide and long-chain base composition on the thermotropic properties of dipalmitoylphosphatidylcholine large unilamellar vesicles containing gangliosides 166
Association to HeLa cells and surface behavior of exogenous gangliosides studied with a fluorescent derivative of GM1 165
Early-Stage Diagnosis of Endogenous Diseases by Swarms of Nanobots: An Applicative Scenario 165
Functionalization with curcumin-derivative and TAT peptide enhances the interaction with human brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide 165
Nanotechnology for neurodegenerative disorders 165
Changes in the composition of detergent-resistant membrane domains of cultured neurons following protein kinase C activation 165
Synthesis of functionalized [F-18]liposomes for preclinical PET imaging in Alzheimer's disease 162
Multi-functional liposomes prevent memory impairment and slow down brain B-amyloid deposition in a mouse model of Alzheimer’s disease. 162
Nanoparticle-based strategy to cross the BBB: the potential for the therapy of Alzheimer’s disease 161
Preparation and use of liposomes for the study of sphingolipid segregation in membrane model systems 158
Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells 157
Stability of Aβ (1-42) peptide fibrils as consequence of environmental modifications 154
Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model 154
The interaction of complement system with abeta-binding liposomes: towards engineering of safer vesicles for the management of alzheimer's disease 152
Proteomics of plasma membrane microdomains 151
Binding of lipid-based nanoparticles to plasma abeta: relevance for new therapeutic strategies in Alzheimer’s disease 151
Nuovi composti triciclici glicofusi, procedimento per la loro produzione e loro impiego quali ligandi dei peptidi β amiloidi (Aβ) 150
Totale 21.428
Categoria #
all - tutte 89.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.345


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.536 227 153 286 288 204 165 269 153 236 258 96 201
2021/20221.838 98 167 176 189 76 175 142 100 104 169 158 284
2022/20233.854 449 1.198 338 396 230 562 37 220 260 25 86 53
2023/20242.561 66 84 137 146 328 678 554 121 158 33 37 219
2024/20254.641 244 541 267 214 430 210 259 213 418 716 380 749
2025/2026216 216 0 0 0 0 0 0 0 0 0 0 0
Totale 26.578